APPS's bull thesis hinges on stabilizing ODS and growing the advertisement segment, leveraging high gross margins in DTX despite lower R&D investments. APPS's shift from waterfall to SDK bidding ...
Sweden's Vicore Pharma has started a clinical trial of a digital therapeutic (DTx) intended to relieve anxiety in patients with idiopathic pulmonary fibrosis (IPF), a debilitating and progressive ...
Otsuka and Click Therapeutics’ Rejoyn has become the first prescription digital therapeutic (DTx) to be approved by the FDA for people with major depressive disorder. Rejoyn (formerly CT-152), a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback